Craft
  • Home
  •  / Supernus Pharmaceuticals
Supernus Pharmaceuticals

Supernus Pharmaceuticals

Revenue

$579.8 M

FY, 2021

Market Capitalization

$1.9 B

2022-11-22

Supernus Pharmaceuticals Summary

Company summary

Overview
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. Its products treat psychiatric and neurological conditions including Attention Deficit/Hyperactivity Disorder (ADHD), epilepsy, Parkinson’s disease (PD), migraine, etc. The company also develops products including for the treatment of ADHD in adults, an apomorphine infusion pump for hypomobility in PD, and a solution for treatment-resistant depression.
Type
Public
Status
Active
Founded
2005
HQ
Rockville, MD, US | view all locations
Website
https://www.supernus.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Jack A. Khattar

    Jack A. Khattar, President and Chief Executive Officer, Director

  • Padmanabh P. Bhatt

    Padmanabh P. Bhatt, Senior Vice President, Chief Scientific Officer, Intellectual Property

  • Kevin T. Anderson, Compliance Officer

    • Timothy C. Dec

      Timothy C. Dec, Senior Vice President, Chief Financial Officer

    LocationsView all

    1 location detected

    • Rockville, MD HQ

      United States

      9715 Key W Ave

    Supernus Pharmaceuticals Financials

    Summary financials

    Revenue (Q3, 2022)
    $177.4M
    Gross profit (Q3, 2022)
    $151.5M
    Net income (Q3, 2022)
    $1.7M
    Cash (Q3, 2022)
    $111.5M
    EBIT (Q3, 2022)
    ($1.5M)
    Enterprise value
    $2.2B

    Blogs

    Footer menu